MedTrace Logo

A First-in-human Study of HCR-188 in Overweight or Obese Otherwise Healthy Volunteers Without Type 2 Diabetes

NCT06845943 · Status: SUSPENDED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-11-26

No results posted yet for this study

Summary

This is a first-in-human study evaluating the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of single and multiple doses of HCR-188 administered as subcutaneous injection(s).

Conditions

  • Obesity and Overweight

Interventions

DRUG

HCR-188

Single (SAD cohorts) or multiple (MAD cohorts) subcutaneous injections

DRUG

Placebo

Single (SAD cohorts) or multiple (MAD cohorts) subcutaneous injections

Sponsors & Collaborators

  • Helicore Biopharma, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-04
Primary Completion
2025-10-22
Completion
2027-12-31
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06845943 on ClinicalTrials.gov